


HSP70 Control Slides





Intended Use

For In Vitro Diagnostic Use.

Summary and Explanation

70 kDa heat shock proteins (HSP70) are found ubiquitously in virtually all living organisms, facilitating protein folding and protecting cells from heat stress and toxic chemicals. HSP70 proteins have 3 functional domains: N-terminal ATPase domain, substrate binding domain, and a C-terminal domain that serves as a "lid" for the substrate binding domain. HSP70 binds tightly to partially synthesized peptides and prevents them from aggregating and rendering nonfunctional. HSP70 also inhibits apoptosis by blocking the recruitment of procaspase-9 to the Apaf-1/dATP/cytochrome c apoptosome complex.HSP70 is shown to be overexpressed in malignant Melanoma and underexpressed in Renal Cell Carcinoma. A variety of tumor cells can express HSP70 with seemingly contradictory functions. Intracellular HSP70 has a cytoprotective function via suppression of apoptosis and lysosomal cell death and extracellular HSP70 can promote tumorigenesis and angiogenesis. Other evidence showed intracellular HSP70 can promote apoptosis and membrane-associated/extracellular HSP70 can elicit antitumor innate and adaptive immune responses. One study evaluated the expression of HSP70, Estrogen Receptor and Ki-67 and assessed the relationship between them in Cervical Squamous Cell Neoplasia. It found that HSP70 may play an important role in tumor cell proliferation and is more related with invasive Squamous Cell Carcinoma than Cervical Intraepithelial Neoplasia, but Estrogen Receptor may be not related with tumor cell proliferation and differentiation. Therefore, HSP70 may be a useful prognostic factor in Cervical Dysplasia and Cancer.

Presentation

Five slides of HSP70 positive tissues, each mounted on Hydrophilic Plus Slides, provided in a plastic mailer.

Catalog No.	Quantity
BSB-9228-CS	5 slides
BSB-3730-CS	5 slides

Storage Store at 20-25°C

Precautions

- 1. For professional users only. Results should be interpreted by a qualified medical professional.
- 2. Ensure proper handling procedures are used with this reagent.
- 3. Always wear personal protective equipment such as a laboratory coat, goggles, and gloves when handling reagents.
- 4. Dispose of unused solution with copious amounts of water.
- 5. Follow safety precautions of the heating device used for epitope retrieval (TintoRetriever Pressure Cooker or similar).
- 8. For additional safety information, refer to Safety Data Sheet for this product.
- 9. For complete recommendations for handling biological specimens, please refer to the CDC document, "Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories" (see References in this document).

Stability

This product is stable up to the expiration date on the product label. Do not use after expiration date listed on package label.

IHC Protocol

- 1. Subject tissues to heat induced epitope retrieval (HIER) using a suitable retrieval solution such as ImmunoDNA Retriever with Citrate (BSB 0020-BSB 0023) or EDTA (BSB 0030-BSB 0033).
- 2. Any of three heating methods may be used:

a. TintoRetriever Pressure Cooker or Equivalent

Place tissues/slides in a staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA and place on trivet in the pressure cooker. Add 1-2 inches of distilled water to the pressure cooker and turn heat to high. Incubate for 15 minutes. Open and immediately transfer slides to room temperature.

b. TintoRetriever PT Module or Water Bath Method

Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA at 95°-99° C. Incubate for 30-60 minutes.

c. Conventional Steamer Method

Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA in a steamer, cover and steam for 30-60 minutes.

- 3. After heat treatment, transfer slides in ImmunoDNA Retriever with Citrate or EDTA to room temperature and let stand for 15-20 minutes.
- 4. For manual staining, perform antibody incubation at ambient temperature. For automated staining methods, perform antibody incubation according to instrument manufacturer's instructions.
- 5. Wash slides with ImmunoDNA washer or DI water.
- 6. Continue IHC staining protocol. Wash slides between each step with ImmunoDNA washer solution.

Abbreviated Immunohistochemical Protocol

A DO TO THAT CALL THE AND THE			
Step	ImmunoDetector AP/HRP	PolyDetector AP/HRP	PolyDetector Plus HRP
Peroxidase/AP Blocker	5 min.	5 min.	5 min
Primary Antibody	30-60 min.	30-60 min.	30-60 min.
1st Step Detection	10 min.	30-45 min.	15 min.
2nd Step Detection	10 min.	Not Applicable	15 min.
Substrate- Chromogen	5-10 min.	5-10 min.	5-10 min.
Counterstain / Coverslip	Varies	Varies	Varies

Abbreviated IF Protocol

71551 CYTACCA II 1 1 0 to CO.		
Step	Incubation Time	
Rinse slides in IF wash buffer	5 minutes	
Drain and wipe excess IF wash buffer off slide		
Conduct remaining steps in the dark		
Apply Antibody	30-60 minutes	
Rinse with 3 changes of IF wash buffer	3x15 minutes each	
Coverslip with IF mounting medium		

Mounting Protocols

For detailed instructions using biodegradable permanent mounting media such as XyGreen PermaMounter (BSB 0169-0174) or organic solvent based resin such as PermaMounter (BSB 0094-0097), refer to PI0174 or PI0097.

Product Limitations

Due to inherent variability present in immunohistochemical procedures (including fixation time of tissues, dilution factor of antibody, retrieval method utilized, and incubation time), optimal performance should be established through the use of positive and negative controls. Results should be interpreted by a qualified medical professional.

References

1. Mayer MP. Gymnastics of molecular chaperones. Mol Cell. 2010;39(3):321-331. doi:10.1016/j.molcel.2010.07.0122. Ricaniadis N, Kataki A, Agnantis N, Androulakis G, Karakousis CP. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol. 2001;27(1):88-93. doi:10.1053/ejso.1999.10183. Ramp U, Mahotka C, Heikaus S, et al. Expression of heat shock protein 70 in renal cell carcinoma and its relation to tumor progression and prognosis. Histol Histopathol. 2007;22(10):1099-1107. doi:10.14670/HH-22.10994. Vostakolaei MA, Hatami-Baroogh L, Babaei G, Molavi O, Kordi S, Abdolalizadeh J. Hsp70 in cancer: A double agent in the battle between survival and death [published online ahead of print, 2020 Nov 10]. J Cell Physiol. 2020;10.1002/jcp.30132. doi:10.1002/jcp.301325. Kim KK, Jang TJ, Kim JR. HSP70 and ER expression in cervical intraepithelial neoplasia and cervical cancer. J Korean Med Sci. 1998;13(4):383-388. doi:10.3346/jkms.1998.13.4.3836. U.S. Department of Health and Human Services: Centers for Disease Control and Prevention. Guidelines for Safe WorkPractices in Human and Animal Medical Diagnostic Laboratories. Supplement / Vol. 61, January 6, 2012. https://www.cdc.gov/mmwr/pdf/other/su6101.pdf

Symbol Key / Légende des symboles/Erläuterung der Symbole

OAdvis EAR AB Storage Temperature Manufacturer Catalog Number Ideon Science Park EC **REP** Limites de température REF **Fabricant** Référence du catalogue Scheelevägen 17 Zulässiger Temperaturbereich Hersteller Bestellnummer SE-223 70 Lund, Sweden Read Instructions for Use In Vitro Diagnostic Medical Device **Expiration Date** Lot Number Consulter les instructions IVD $\begin{bmatrix} \mathbf{i} \end{bmatrix}$ LOT Dispositif médical de diagnostic in vitro Utiliser jusque Code du lot d'utilisation In-Vitro-Diagnostikum Verwendbar bis Chargenbezeichnung Gebrauchsanweisung beachten

